文献速递急腹症与外科感染围术期管理与 ERAS

减少阿片类药物的多模式疼痛方案降低阿片类药物滥用高风险创伤患者的阿片暴露与疼痛:MAST试验二次分析

An opioid-minimizing multimodal pain regimen reduces opioid exposure and pain in trauma-injured patients at high risk for opioid misuse: Secondary analysis from the mast trial.
PubMed 文献 · Surgery · 2023-10-13

本研究为MAST随机试验的二次分析,纳入631例创伤患者,按阿片风险工具分为低风险和高风险,评估减少阿片类药物的多模式疼痛方案对比原多模式疼痛方案对阿片暴露、出院阿片处方和疼痛评分的影响。贝叶斯分析显示该方案在低风险和高风险组均降低吗啡毫克当量/天,出院阿片处方和疼痛评分的调节效应仅在高风险组观察到。

要点

  • 减少阿片类药物的多模式疼痛方案在低风险和高风险组均降低吗啡毫克当量/天。
  • 出院阿片处方仅在高风险组观察到调节效应:63% vs 77%,相对风险=0.86,95%贝叶斯可信区间[0.66-1.08],后验概率(相对风险<1)=90%。
  • 疼痛评分仅在高风险组观察到调节效应:b=3.8,95%贝叶斯可信区间[3.2-4.4] vs b=4.0,95%贝叶斯可信区间[3.4-4.6],后验概率(b<0)=87%。

核心结论

  • 本研究首次显示阿片类药物滥用风险对减少阿片类药物的多模式疼痛方案有效性具有调节影响。
  • 阿片风险工具有助于识别高风险患者,对于这些患者推荐使用MAST多模式疼痛方案进行围术期疼痛管理。

研究设计与样本

  • MAST随机试验的二次分析,纳入631例创伤患者,通过阿片风险工具分为低风险或高风险。
  • 比较减少阿片类药物的多模式疼痛方案(口服对乙酰氨基酚、萘普生、加巴喷丁、利多卡因贴剂、按需阿片类药物)与原多模式疼痛方案(静脉后口服对乙酰氨基酚、48小时塞来昔布和普瑞巴林,随后萘普生和加巴喷丁、定时曲马多、按需阿片类药物)。
  • 试验于2018年4月至2019年3月进行,采用贝叶斯分析评估阿片风险工具风险(高/低)对方案效果( versus 原方案)在阿片暴露(吗啡毫克当量/天)、出院阿片处方和疼痛评分上的调节影响。

主要发现

  • MAST多模式疼痛方案在低风险和高风险组均有效降低吗啡毫克当量/天。
  • 出院阿片处方观察到调节效应,MAST方案仅在高风险组有效:63% vs 77%,相对风险=0.86,95%贝叶斯可信区间[0.66-1.08],后验概率(相对风险<1)=90%。
  • 疼痛评分观察到调节效应,MAST方案仅在高风险组有效:b=3.8,95%贝叶斯可信区间[3.2-4.4] vs b=4.0,95%贝叶斯可信区间[3.4-4.6],后验概率(b<0)=87%。

临床怎么用

  • 作者认为阿片风险工具有助于识别高风险患者,对于这些患者推荐使用MAST多模式疼痛方案进行围术期疼痛管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Screening to identify patients at risk for opioid misuse after trauma is recommended but not commonly used to guide perioperative opioid management interventions. The Multimodal Analgesic Strategies for Trauma trial demonstrated that an opioid-minimizing multimodal pain regimen reduced opioid exposure in a heterogeneous trauma patient population. Here, we assess the efficacy of the Multimodal Analgesic Strategies for Trauma multimodal pain regimen in a critical patient subgroup who screened at high risk for opioid misuse. METHODS: The Multimodal Analgesic Strategies for Trauma trial compared an opioid-minimizing multimodal pain regimen (oral acetaminophen, naproxen, gabapentin, lidocaine patch, as-needed opioid) against an original multimodal pain regimen (intravenous followed by oral acetaminophen, 48-hour celecoxib and pregabalin, followed by naproxen and gabapentin, scheduled tramadol, as-needed opioid), in a randomized trial conducted from April 2018 to March 2019. A total of 631 enrolled patients were classified either as low- or high-risk via the Opioid Risk Tool. Bayesian analyses evaluated the moderating influence of Opioid Risk Tool risk (high/low) on the effect of Multimodal Analgesic Strategies for Trauma multimodal pain regimen (versus original) on opioid exposure (morphine milligram equivalents/day), opioids prescribed at discharge, and pain scores. RESULTS: Multimodal Analgesic Strategies for Trauma multimodal pain regimen effectively reduced morphine milligram equivalents/day in low- and high-Opioid Risk Tool risk groups. Moderation was observed for opioids at discharge and pain scores; Multimodal Analgesic Strategies for Trauma multimodal pain regimen was effective in the high-risk group only (opioids at discharge: 63% vs 77%, relative risk = 0.86, 95% Bayesian credible interval [0.66-1.08], posterior probability (relative risk <1) = 90%; pain scores: b = 3.8, 95% Bayesian credible interval [3.2-4.4] vs b = 4.0, 95% Bayesian credible interval [3.4-4.6], posterior probability (b <0) = 87%). CONCLUSION: This study is the first to show the moderating influence of opioid misuse risk on the effectiveness of an opioid-minimizing multimodal pain regimen. The Opioid Risk Tool was useful in identifying high-risk patients for whom the Multimodal Analgesic Strategies for Trauma multimodal pain regimen is recommended for perioperative pain management.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. de Dios C, Suchting R, Green C, et al. An opioid-minimizing multimodal pain regimen reduces opioid exposure and pain in trauma-injured patients at high risk for opioid misuse: Secondary analysis from the mast trial. Surgery. 2023. PMID: 37839970. doi:10.1016/j.surg.2023.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。